L. Johnetta Blakely

Barriers to biomarker testing: An analysis of insurance denials at Tennessee Oncology.

Katherine Baker, Samyukta Mullangi, Larry Edward Bilbrey, Thomas Stricker et autres

280 Background: Comprehensive biomarker testing allows for selection of molecularly targeted therapies that improve patient outcomes and is considered a best practice. Despite its importance, access to biomarker testing is often hindered by gaps in insurance coverage, limiting the potential for personalized …

us (code pays fourni par la source)

Delays in new patient scheduling: A shift from paper to patient.

An Thi My Tran, Alexis Reese, Larry Edward Bilbrey, L. Johnetta Blakely

492 Background: Tennessee Oncology (TO) is a large community-based practice receiving 125 new patient referrals per day for hematologic and oncologic care throughout 35 clinics across the states of Tennessee and Georgia. Institutional guidelines dictate a three-business day window from time of …

us (code pays fourni par la source)

Enhancing end-of-life quality metrics: The role of palliative care in a community oncology practice.

Katherine Baker, Aaron J. Lyss, Larry Edward Bilbrey, L. Johnetta Blakely et autres

85 Background: As value-based payment (VBP) models expand in oncology, care teams adopt innovative strategies to improve outcomes, enhance patient experience, and meet evolving quality metrics (QMs). These changes require reassessing traditional population health QMs to ensure they reflect current practices and …

us (code pays fourni par la source)

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab

L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush et autres

Aim: This ambispective observational study assessed the impact of Noona, an electronic patient-reported outcomes (ePRO) platform, for patients with non-small cell lung cancer (NSCLC) treated in a community oncology setting. Methods: Adults with advanced NSCLC, ECOG performance status of 0–2, who received …

us (code pays fourni par la source)

Increased biosimilar options in oncology and impact on administrative burden caused by drug switches: Implications of step therapy.

Stacey L Poole, L. Johnetta Blakely, Stephen M. Schleicher, Natalie R. Dickson

18 Background: Within drug classes, some payers require a particular drug to be tried and failed first, before reimbursing other drugs within the same drug . This is called a step-edit. These step edits are mandated despite physician or patient preference. With …

us (code pays fourni par la source)

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.

Pedram Razavi, Mehnaj Ahmed, Ashley Roush, Rohan Parikh et autres

e12533 Background: Despite improved management of HR+/HER2− EBC, pts experience recurrences while on or up to decades after ending standard-of-care (SOC) ET. Addition of adjuvant (adj) cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), ribociclib and abemaciclib, to SOC ET resulted in significant improvement of …

us (code pays fourni par la source)

Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Natalie R. Dickson, Karen Beauchamp, Toni S. Perry, Ashley Roush et autres

BACKGROUND: Utilization of electronic patient-reported outcome (ePRO) tools to monitor symptoms in patients undergoing cancer treatment has shown clinical benefits. Tennessee Oncology (TO) implemented an ePRO platform in 2019, allowing patients to report their health status online. We conducted a real-world, multicenter, …

us (code pays fourni par la source)

Building Efficiency and Scaling With a Remote Genetic Counseling Program

Smita K. Rao, L. Johnetta Blakely, Kate Small, Stephen M. Schleicher et autres

Purpose A third-party telemedicine (TM) genetic counseling program was initiated at a large community oncology practice spanning 35 clinical sites with 110 clinicians and 97 advanced practice providers throughout Tennessee and Georgia. Patients and Methods Appropriate patients were referred through the electronic …

Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology.

L. Johnetta Blakely, Zheng‐Yi Zhou, Marie Louise Edwards, Kirthana Sarathy et autres

364 Background: Myelosuppression is common in patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving chemotherapy and poses a high burden for patients and oncology practices. This study described burden of myelosuppression among patients with ES-SCLC treated with chemotherapy using data from Tennessee …

us (code pays fourni par la source)

Trend in breakdown of total cost of care for medical oncology over time: Learnings from the Oncology Care Model and implications for future oncology value-based care.

L. Owens, Larry Edward Bilbrey, Natalie R. Dickson, L. Johnetta Blakely et autres

69 Background: Tennessee Oncology (TO) is a large, outpatient community oncology practice with over 200 providers and 35 clinical sites of care across Tennessee and northern Georgia. As an Oncology Care Model (OCM) participant, TO received claims data from Medicare during its …

us (code pays fourni par la source)

Impact of early detection on cancer curability: A modified Delphi panel study

Lee S. Schwartzberg, Michael S. Broder, Sikander Ailawadhi, Himisha Beltran et autres

Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate which of 20 solid tumors, representing >40 American Joint Committee on Cancer …

us (code pays fourni par la source)

Provider-led advance care planning in community oncology: A successful multidisciplinary quality improvement intervention.

Sandhya Mudumbi, L. Owens, Christy L. Schneider, Susan A Frailley et autres

209 Background: Advanced care planning (ACP) is an important aspect of shared decision making in cancer treatment. Due to its importance, in 2016, Medicare expanded coverage and reimbursement for advance care planning (ACP) services (CPT codes 99497 and 99498). Despite this, ACP …

us (code pays fourni par la source)